http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 29 May 2026 16:11:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Benitec+Biopharma+Inc.++++For%3A+May+22/26575218.html si-local-file:///var/storage/secattach/20260529/26575218.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Benitec+Biopharma+Inc.++++For%3A+May+22/26575218.html Fri, 29 May 2026 16:11:00 -0400 BNTC O.41859586 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Benitec+Biopharma+Inc.++++For%3A+May+22/26575218.html si-local-file:///var/storage/secattach/20260529/26575218.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Benitec+Biopharma+Inc.++++For%3A+May+22/26575218.html Fri, 29 May 2026 16:11:00 -0400 BNTC O.41859586 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Benitec+Biopharma+Inc.++++For%3A+May+26++Filed+by%3A+Friedman+David+Matthew/26569458.html si-local-file:///var/storage/secattach/20260528/26569458.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Benitec+Biopharma+Inc.++++For%3A+May+26++Filed+by%3A+Friedman+David+Matthew/26569458.html Thu, 28 May 2026 21:10:00 -0400 BNTC O.41859586 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Benitec+Biopharma+Inc.++++For%3A+May+26++Filed+by%3A+Friedman+David+Matthew/26569458.html si-local-file:///var/storage/secattach/20260528/26569458.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Benitec+Biopharma+Inc.++++For%3A+May+26++Filed+by%3A+Friedman+David+Matthew/26569458.html Thu, 28 May 2026 21:10:00 -0400 BNTC O.41859586 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Benitec+Biopharma+Inc.++++For%3A+May+22++Filed+by%3A+Friedman+David+Matthew/26569456.html si-local-file:///var/storage/secattach/20260528/26569456.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Benitec+Biopharma+Inc.++++For%3A+May+22++Filed+by%3A+Friedman+David+Matthew/26569456.html Thu, 28 May 2026 21:09:00 -0400 BNTC O.41859586 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Benitec+Biopharma+Inc.++++For%3A+May+22++Filed+by%3A+Friedman+David+Matthew/26569456.html si-local-file:///var/storage/secattach/20260528/26569456.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Benitec+Biopharma+Inc.++++For%3A+May+22++Filed+by%3A+Friedman+David+Matthew/26569456.html Thu, 28 May 2026 21:09:00 -0400 BNTC O.41859586 http://www.streetinsider.com/Analyst+Comments/Benitec+BioPharma+%28BNTC%29+Reiterated+at+Market+Outperform+by+Citizens+on+Q3+Update/26510139.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $24.00 price target on Benitec BioPharma (NASDAQ: BNTC).</p><p>The analyst commented, "We continue to be very encouraged by the high-dose results that, in a first patient, seem to indicate that efficacy can be significantly improved at the higher dose with a safety margin. A second key point of confidence is that 24-month vs. 12-month data in the low-dose cohort indicate that benefit continues to increase, indicating additional room for improvement. Overall, 30% to 80% improvements across endpoints, already at the low dose, point to potential for disease modification in a setting http://www.streetinsider.com/Analyst+Comments/Benitec+BioPharma+%28BNTC%29+Reiterated+at+Market+Outperform+by+Citizens+on+Q3+Update/26510139.html Mon, 18 May 2026 07:20:13 -0400 BNTC http://www.streetinsider.com/Earnings/Benitec+Biopharma+%28BNTC%29+Misses+Q3+EPS+by+24c/26490717.html <p>Benitec Biopharma (NASDAQ: BNTC) reported Q3 EPS of ($0.24).</p><p>For earnings history and earnings-related data on Benitec Biopharma (BNTC) <a href="http://www.streetinsider.com/ec_earnings.php?q=BNTC">click here</a>.</p> http://www.streetinsider.com/Earnings/Benitec+Biopharma+%28BNTC%29+Misses+Q3+EPS+by+24c/26490717.html Thu, 14 May 2026 08:35:19 -0400 BNTC http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Benitec+Biopharma+Inc.++++For%3A+Mar+31/26490473.html si-local-file:///var/storage/secattach/20260514/26490473.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Benitec+Biopharma+Inc.++++For%3A+Mar+31/26490473.html Thu, 14 May 2026 08:11:00 -0400 BNTC O.41859586 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Benitec+Biopharma+Inc.++++For%3A+Mar+31/26490473.html si-local-file:///var/storage/secattach/20260514/26490473.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Benitec+Biopharma+Inc.++++For%3A+Mar+31/26490473.html Thu, 14 May 2026 08:11:00 -0400 BNTC O.41859586 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Benitec+Biopharma+Inc.++++For%3A+May+14/26490452.html si-local-file:///var/storage/secattach/20260514/26490452.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Benitec+Biopharma+Inc.++++For%3A+May+14/26490452.html Thu, 14 May 2026 08:09:00 -0400 BNTC O.41859586 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Benitec+Biopharma+Inc.++++For%3A+May+14/26490452.html si-local-file:///var/storage/secattach/20260514/26490452.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Benitec+Biopharma+Inc.++++For%3A+May+14/26490452.html Thu, 14 May 2026 08:09:00 -0400 BNTC O.41859586 http://www.streetinsider.com/Corporate+News/Benitec+Biopharma+reports+Q3+2026+results%2C+advances+BB-301+trial/26490345.html <p>Benitec Biopharma Inc. (NASDAQ: BNTC) reported third quarter 2026 financial results and provided updates on its BB-301 clinical development program for Oculopharyngeal Muscular Dystrophy.</p> <p>The company reported a net loss of $11.9 million, or $0.24 per share, for the quarter ended March 31, 2026, compared to a net loss of $14.5 million, or $0.38 per share, in the same period last year. Total expenses decreased to $13.6 million from $15.3 million year-over-year.</p> <p>Research and development expenses were $6.3 million, compared to $6.5 million in the prior year quarter. General and administrative expenses decreased to $7.3 million from $8.8 million. As of March http://www.streetinsider.com/Corporate+News/Benitec+Biopharma+reports+Q3+2026+results%2C+advances+BB-301+trial/26490345.html Thu, 14 May 2026 08:01:22 -0400 A.06822034 A.26566475 BNTC O.07320020 O.20026344 O.41859586 http://www.streetinsider.com/Corporate+News/Benitec+Biopharma+reports+Q3+2026+results%2C+advances+BB-301+trial/26490345.html <p>Benitec Biopharma Inc. (NASDAQ: BNTC) reported third quarter 2026 financial results and provided updates on its BB-301 clinical development program for Oculopharyngeal Muscular Dystrophy.</p> <p>The company reported a net loss of $11.9 million, or $0.24 per share, for the quarter ended March 31, 2026, compared to a net loss of $14.5 million, or $0.38 per share, in the same period last year. Total expenses decreased to $13.6 million from $15.3 million year-over-year.</p> <p>Research and development expenses were $6.3 million, compared to $6.5 million in the prior year quarter. General and administrative expenses decreased to $7.3 million from $8.8 million. As of March http://www.streetinsider.com/Corporate+News/Benitec+Biopharma+reports+Q3+2026+results%2C+advances+BB-301+trial/26490345.html Thu, 14 May 2026 08:01:22 -0400 A.06822034 A.26566475 BNTC O.07320020 O.20026344 O.41859586 http://www.streetinsider.com/Corporate+News/Benitec+Biopharma+reports+Q3+2026+results%2C+advances+BB-301+trial/26490345.html <p>Benitec Biopharma Inc. (NASDAQ: BNTC) reported third quarter 2026 financial results and provided updates on its BB-301 clinical development program for Oculopharyngeal Muscular Dystrophy.</p> <p>The company reported a net loss of $11.9 million, or $0.24 per share, for the quarter ended March 31, 2026, compared to a net loss of $14.5 million, or $0.38 per share, in the same period last year. Total expenses decreased to $13.6 million from $15.3 million year-over-year.</p> <p>Research and development expenses were $6.3 million, compared to $6.5 million in the prior year quarter. General and administrative expenses decreased to $7.3 million from $8.8 million. As of March http://www.streetinsider.com/Corporate+News/Benitec+Biopharma+reports+Q3+2026+results%2C+advances+BB-301+trial/26490345.html Thu, 14 May 2026 08:01:22 -0400 A.06822034 A.26566475 BNTC O.07320020 O.20026344 O.41859586 http://www.streetinsider.com/Corporate+News/Benitec+Biopharma+reports+Q3+2026+results%2C+advances+BB-301+trial/26490345.html <p>Benitec Biopharma Inc. (NASDAQ: BNTC) reported third quarter 2026 financial results and provided updates on its BB-301 clinical development program for Oculopharyngeal Muscular Dystrophy.</p> <p>The company reported a net loss of $11.9 million, or $0.24 per share, for the quarter ended March 31, 2026, compared to a net loss of $14.5 million, or $0.38 per share, in the same period last year. Total expenses decreased to $13.6 million from $15.3 million year-over-year.</p> <p>Research and development expenses were $6.3 million, compared to $6.5 million in the prior year quarter. General and administrative expenses decreased to $7.3 million from $8.8 million. As of March http://www.streetinsider.com/Corporate+News/Benitec+Biopharma+reports+Q3+2026+results%2C+advances+BB-301+trial/26490345.html Thu, 14 May 2026 08:01:22 -0400 A.06822034 A.26566475 BNTC O.07320020 O.20026344 O.41859586 http://www.streetinsider.com/Corporate+News/Benitec+Biopharma+reports+Q3+2026+results%2C+advances+BB-301+trial/26490345.html <p>Benitec Biopharma Inc. (NASDAQ: BNTC) reported third quarter 2026 financial results and provided updates on its BB-301 clinical development program for Oculopharyngeal Muscular Dystrophy.</p> <p>The company reported a net loss of $11.9 million, or $0.24 per share, for the quarter ended March 31, 2026, compared to a net loss of $14.5 million, or $0.38 per share, in the same period last year. Total expenses decreased to $13.6 million from $15.3 million year-over-year.</p> <p>Research and development expenses were $6.3 million, compared to $6.5 million in the prior year quarter. General and administrative expenses decreased to $7.3 million from $8.8 million. As of March http://www.streetinsider.com/Corporate+News/Benitec+Biopharma+reports+Q3+2026+results%2C+advances+BB-301+trial/26490345.html Thu, 14 May 2026 08:01:22 -0400 A.06822034 A.26566475 BNTC O.07320020 O.20026344 O.41859586 http://www.streetinsider.com/Corporate+News/Benitec+Biopharma+reports+Q3+2026+results%2C+advances+BB-301+trial/26490345.html <p>Benitec Biopharma Inc. (NASDAQ: BNTC) reported third quarter 2026 financial results and provided updates on its BB-301 clinical development program for Oculopharyngeal Muscular Dystrophy.</p> <p>The company reported a net loss of $11.9 million, or $0.24 per share, for the quarter ended March 31, 2026, compared to a net loss of $14.5 million, or $0.38 per share, in the same period last year. Total expenses decreased to $13.6 million from $15.3 million year-over-year.</p> <p>Research and development expenses were $6.3 million, compared to $6.5 million in the prior year quarter. General and administrative expenses decreased to $7.3 million from $8.8 million. As of March http://www.streetinsider.com/Corporate+News/Benitec+Biopharma+reports+Q3+2026+results%2C+advances+BB-301+trial/26490345.html Thu, 14 May 2026 08:01:22 -0400 A.06822034 A.26566475 BNTC O.07320020 O.20026344 O.41859586 http://www.streetinsider.com/Press+Releases/Benitec+Biopharma+Releases+Third+Quarter+2026+Financial+Results+and+Provides+Operational+Update/26490337.html <ul type="disc"><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatment and further improvements in depth of response following treatment with high dose BB-301 at the 3-month post-treatment follow-up time-point, with both doses demonstrating disease modifying outcomes</em><br/><br/></li><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>BB-301 Phase 1b/2a interim clinical study results selected for oral presentation at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting on May 15</em><br/><br/></li><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>Advancement of Cohort 2 enrollment continues as Patient 1 and http://www.streetinsider.com/Press+Releases/Benitec+Biopharma+Releases+Third+Quarter+2026+Financial+Results+and+Provides+Operational+Update/26490337.html Thu, 14 May 2026 08:00:00 -0400 A.06822034 A.26566475 BNTC O.07320020 O.20026344 O.41859586 http://www.streetinsider.com/Press+Releases/Benitec+Biopharma+Releases+Third+Quarter+2026+Financial+Results+and+Provides+Operational+Update/26490337.html <ul type="disc"><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatment and further improvements in depth of response following treatment with high dose BB-301 at the 3-month post-treatment follow-up time-point, with both doses demonstrating disease modifying outcomes</em><br/><br/></li><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>BB-301 Phase 1b/2a interim clinical study results selected for oral presentation at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting on May 15</em><br/><br/></li><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>Advancement of Cohort 2 enrollment continues as Patient 1 and http://www.streetinsider.com/Press+Releases/Benitec+Biopharma+Releases+Third+Quarter+2026+Financial+Results+and+Provides+Operational+Update/26490337.html Thu, 14 May 2026 08:00:00 -0400 A.06822034 A.26566475 BNTC O.07320020 O.20026344 O.41859586 http://www.streetinsider.com/Press+Releases/Benitec+Biopharma+Releases+Third+Quarter+2026+Financial+Results+and+Provides+Operational+Update/26490337.html <ul type="disc"><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatment and further improvements in depth of response following treatment with high dose BB-301 at the 3-month post-treatment follow-up time-point, with both doses demonstrating disease modifying outcomes</em><br/><br/></li><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>BB-301 Phase 1b/2a interim clinical study results selected for oral presentation at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting on May 15</em><br/><br/></li><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>Advancement of Cohort 2 enrollment continues as Patient 1 and http://www.streetinsider.com/Press+Releases/Benitec+Biopharma+Releases+Third+Quarter+2026+Financial+Results+and+Provides+Operational+Update/26490337.html Thu, 14 May 2026 08:00:00 -0400 A.06822034 A.26566475 BNTC O.07320020 O.20026344 O.41859586 http://www.streetinsider.com/Press+Releases/Benitec+Biopharma+Releases+Third+Quarter+2026+Financial+Results+and+Provides+Operational+Update/26490337.html <ul type="disc"><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatment and further improvements in depth of response following treatment with high dose BB-301 at the 3-month post-treatment follow-up time-point, with both doses demonstrating disease modifying outcomes</em><br/><br/></li><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>BB-301 Phase 1b/2a interim clinical study results selected for oral presentation at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting on May 15</em><br/><br/></li><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>Advancement of Cohort 2 enrollment continues as Patient 1 and http://www.streetinsider.com/Press+Releases/Benitec+Biopharma+Releases+Third+Quarter+2026+Financial+Results+and+Provides+Operational+Update/26490337.html Thu, 14 May 2026 08:00:00 -0400 A.06822034 A.26566475 BNTC O.07320020 O.20026344 O.41859586 http://www.streetinsider.com/Press+Releases/Benitec+Biopharma+Releases+Third+Quarter+2026+Financial+Results+and+Provides+Operational+Update/26490337.html <ul type="disc"><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatment and further improvements in depth of response following treatment with high dose BB-301 at the 3-month post-treatment follow-up time-point, with both doses demonstrating disease modifying outcomes</em><br/><br/></li><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>BB-301 Phase 1b/2a interim clinical study results selected for oral presentation at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting on May 15</em><br/><br/></li><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>Advancement of Cohort 2 enrollment continues as Patient 1 and http://www.streetinsider.com/Press+Releases/Benitec+Biopharma+Releases+Third+Quarter+2026+Financial+Results+and+Provides+Operational+Update/26490337.html Thu, 14 May 2026 08:00:00 -0400 A.06822034 A.26566475 BNTC O.07320020 O.20026344 O.41859586 http://www.streetinsider.com/Press+Releases/Benitec+Biopharma+Releases+Third+Quarter+2026+Financial+Results+and+Provides+Operational+Update/26490337.html <ul type="disc"><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatment and further improvements in depth of response following treatment with high dose BB-301 at the 3-month post-treatment follow-up time-point, with both doses demonstrating disease modifying outcomes</em><br/><br/></li><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>BB-301 Phase 1b/2a interim clinical study results selected for oral presentation at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting on May 15</em><br/><br/></li><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>Advancement of Cohort 2 enrollment continues as Patient 1 and http://www.streetinsider.com/Press+Releases/Benitec+Biopharma+Releases+Third+Quarter+2026+Financial+Results+and+Provides+Operational+Update/26490337.html Thu, 14 May 2026 08:00:00 -0400 A.06822034 A.26566475 BNTC O.07320020 O.20026344 O.41859586 http://www.streetinsider.com/Globe+Newswire/Benitec+Biopharma+Releases+Third+Quarter+2026+Financial+Results+and+Provides+Operational+Update/26490337.html <ul type="disc"><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatment and further improvements in depth of response following treatment with high dose BB-301 at the 3-month post-treatment follow-up time-point, with both doses demonstrating disease modifying outcomes</em><br/><br/></li><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>BB-301 Phase 1b/2a interim clinical study results selected for oral presentation at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting on May 15</em><br/><br/></li><li style="list-style-position:inside; margin-bottom:0.9pt; text-align:center;"><em>Advancement of Cohort 2 enrollment continues as Patient 1 and http://www.streetinsider.com/Globe+Newswire/Benitec+Biopharma+Releases+Third+Quarter+2026+Financial+Results+and+Provides+Operational+Update/26490337.html Thu, 14 May 2026 08:00:00 -0400 A.06822034 A.26566475 BNTC O.07320020 O.20026344 O.41859586